(type de caractère : century gothic en 10 pour le texte, 16 pour le titre)

List of Publications
Original articles, peer-reviewed

1. Steffens S, Thiel H-J, Behrens S-E (1999). The RNA-dependent RNA polymerases
of different members of the family Flaviviridae exhibit similar properties in vitro. Journal of General Virology, 80(Pt 10): 2583-90 2. Steffens S, Frank S, Fischer U, Heuser C, Meyer KL, Dobberstein K-U, Rainov NG,
Kramm CM (2000). EGFP fusion proteins of HSV-TK and cytochrome P450 4B1: Applications for prodrug-activating enzyme gene therapy. Cancer Gene Therapy, 7(5): 806-12
3. Frank S, Steffens S, Fischer U, Heuser C, Rainov NG, Kramm CM (2002).
Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy. Cancer Gene Therapy, 9(2): 178-88
4. Kramm CM, Korholz D, Rainov NG, Niehues T, Fischer U, Steffens S, Frank S,
Banning U, Horneff G, Schroten H, Burdach S (2002). Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient. Neuropediatrics, 33(1): 6-9 5. Steffens S, Sandquist A, Frank S, Fischer U, Lex C, Rainov NG, Kramm CM (2004).
A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter. Pediatric Research, 56(2): 268-7 6. Veillard NR, Steffens S, Burger F, Pelli G, Mach F (2004). Differential expression
patterns of pro- and anti-inflammatory mediators during atherogenesis in mice. Arteriosclerosis, Thrombosis and Vascular Biology, 24(12):2339-44
7. Sena-Esteves M, Tebbets J, Steffens S, Crombleholme T, Flake A (2004). Optimized
large-scale production of high titer lentivirus vector pseudotypes. Journal of Virological Methods, 122(2):131-9
8. Steffens S, Tebbets J, Kramm CM, Flake A, Sena-Esteves M (2004). Transduction of
human glial and neuronal tumor cells with different lentivirus vector pseudotypes. Journal of Neurooncology, 70(3):281-8
9. Fischer U, Steffens S, Frank S, Rainov NG, Schulze-Osthoff K, Kramm CM (2005).
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene, 24(7):1231-43 10. Arnaud C, Burger F, Steffens S, Veillard N, Nguyen TH, Trono D, Mach F (2005).
Statins reduce C-Reactive Protein in hepatocytes: New evidence for anti-inflammatory effects of statins. Arteriosclerosis, Thrombosis and Vascular Biology, 25(6):1231-6 11. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A,
Frossard JL, Mach F (2005). Low dose oral cannabinoid-therapy reduces progression of atherosclerosis in mice. Nature, 434(7034):782-6 12. Veillard NR, Steffens S, Pelli G, Lu GB, Kwak BR, Gerard C, Charo IF, Mach F
(2005). Differential influence of the chemokine receptors CCR2 and CXCR3 in the development of atherosclerosis in vivo. Circulation, 112(6):870-8 13. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, Mach F
(2006). Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis, 188(1): 51-8
14. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach
F (2006). Short-term treatment with CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation, 114(18):1977-84
15. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E,
Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C (2007). CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arteriosclerosis, Thrombosis and Vascular Biology, 27(2):373-9
16. Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, Bertolotto M, Mach F,
Dallegri F, Ottonello L (2008). Tumor necrosis factor-alpha (TNF-alpha) induces neutrophil migration to the CC chemokine CCL3 (MIP-1 alpha) through defined signaling pathways. Cellular Signalling, 20(3):557-68
17. Montecucco F, Burger F, Mach F, Steffens S (2008). The CB2 cannabinoid receptor
agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. American Journal of Physiology – Heart and Circulatory Physiology, 294(3): H1145-55
18. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F
(2008). A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arteriosclerosis, Thrombosis and Vascular Biology, 28(6):1090-6
19. Montecucco F#, Steffens S#, Burger F, Mach F (2008). C-reactive protein (CRP)
induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. Journal of Leukocyte Biology, 84(4):1109-19 #Equal contribution. 20. Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S, Mach F (2009).
Statins inhibit C-reactive protein (CRP)-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology, 48(3):233-42
21. Montecucco F#, Matias I#, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther
V, Mach F, Steffens S*, Di Marzo V* (2009). Regulation and possible role of
endocannabinoids and related mediators in hypercholesterolemic mice with
atherosclerosis.
Atherosclerosis, 205(2):433-41
#Equal first/*last author contribution.
22. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F and Steffens S (2009). CB2 cannabinoid receptor activation is cardioprotective in a
mouse model of ischemia/reperfusion.
Journal of Molecular and Cellular Cardiology,
46(5):612-20
23. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C, Weber C,
Proudfoot A, Mach F, Arnaud C (2010). Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. Journal of Molecular and Cellular Cardiology, 48(4):789-98 24. Montecucco F, Lenglet S, Bertolotto M, Pelli G, Gayet-Ageron A, Palombo D, Pane B, Spinella G, Steffens S, Raffaghello L, Pistoia V, Ottonello L, Pende A, Dallegri F, Mach
F (2010). Systemic and intraplaque mediators of inflammation are increased in
patients symptomatic for ischemic stroke.
Stroke, 41(7):1394-404
25. Thomas A, Deglon J, Lenglet S, Mach F, Mangin P, Wolfender J-L, Steffens S, Staub
C (2010). High-Throughput Phospholipidic Fingerprinting by Online Desorption of Dried Spots and Quadrupole-Linear Ion Trap Mass Spectrometry: Evaluation of Atherosclerosis Biomarkers in Mouse Plasma. Analytical Chemistry, 82(15):6687-94 26. Frossard JL, Lenglet S, Montecucco F, Steffens S, Galan K, Pelli G, Spahr L, Mach
F, Hadengue A (2011). Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis associated lung injury. Journal of Clinical Pathology, 64(5): 387-93 27. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F,
Schindler TH (2011). Elevated endocannabinoid plasma levels are associated with
coronary circulatory dysfunction in obesity.
European Heart Journal, 32(11) : 1369-78

Review articles, peer-reviewed
1. Steffens S, Mach F (2004). Inflammation and atherosclerosis. Herz 29(8):741-8
2. Steffens S, Mach F (2004). Antiinflammatory properties of statins. Seminars in

3. Steffens S, Mach F (2006). Toward a therapeutic use of cannabinoid CB(2) receptor
in atherosclerosis. Medecine Science (Paris), 22(1): 7-9 4. Steffens S, Mach F (2006). Towards a therapeutic use of selective cannabinoid
receptor ligands for atherosclerosis. Future Cardiology, 2(1): 49-53
5. Steffens S, Mach F (2006). Drug insight: immunomodulatory effects of statins-
potential benefits for renal patients? Nature Clinical Practice Nephrology, 2(7):378-87 6. Steffens S, Mach F (2006). Cannabinoid receptors in atherosclerosis. Current

7. Braunersreuther V, Mach F, Steffens S (2007). The specific role of chemokines in
atherosclerosis. Thrombosis and Haemostasis, 97(5): 714-21
8. Mach F, Montecucco F, Steffens S (2008). Cannabinoid receptors in acute and
chronic complications of atherosclerosis. British Journal of Pharmacology, 153(2): 290-8
9. Montecucco F, Steffens S, Mach F (2007). The immune response is involved in
atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clinical & Developmental Immunology, 2007: 75805 10. Mach F, Steffens S (2008). The role of the endocannabinoid system in
atherosclerosis. Journal of Neuroendocrinology, 20(Suppl 1): 53-7 11. Montecucco F, Steffens S, Mach F (2008). Insulin resistance: a pro-atherosclerotic
condition associated with lipid-induced signaling dysfunction? Mediators of Inflammation, 2008: 767623
12. Mach F, Montecucco F, Steffens S (2009). Blockage of the endocannabinoid system
with rimonabant in cardiovascular risk. Pharmacological Reports, 61(1): 13-21 13. Pacher P, Steffens S (2009). The emerging role of the endocannabinoid system in
cardiovascular disease. Seminars in Immunopathology, 31(1): 63-77 14. Steffens S#, Montecucco F#, Mach F (2009). The inflammatory response as a target
to reduce myocardial ischemia and reperfusion injury. Thrombosis and Hemostasis, 102(2): 240-7 #Equal contribution. 15. Tuma R, Steffens S (2011). Targeting the endocannabinod system to limit
myocardial and cerebral ischemic and reperfusion injury. Current Pharmaceutical Biotechnology, Apr 6 [Epub ahead of print] 16. Thomas A, Lenglet S, Mach F, Déglon J, Mangin P, Chaurand P, Wolfender J-L, Steffens S, Staub C. Mass spectrometry for evaluation of cardiovascular diseases
based on proteomic and lipidomic strategies.
Thrombosis and Hemostasis, May 26
106(1) [Epub ahead of print]

Other publications

1. Steffens S (1997). Identification of an RNA-dependent RNA-polymerase of
pestiviruses. Diploma thesis, Justus-Liebig-Universität, Fachbereich Biologie, Giessen, Deutschland 2. Steffens S (2002). Development of a tumorspecific suicide gene therapy for
neuroblastomas. PhD thesis, Heinrich-Heine-Universität Düsseldorf, Deutschland 3. Steffens S (2006). Cannabinoids for therapeutic use in atherosclerosis.

4. Steffens S, Mach F (2007). Effets du système cannabinoïde sur les maladies
cardiovasculaires. Cardiovasc, 6:10-12 5. Montecucco F, Steffens S, Mach F (2007). Inflammation as a coronary risk factor.
6. Mach F, Montecucco F, Steffens S (2008). Role of the endocannabinoid system in
atherosclerosis. CMR Journal, (Official Journal of the International Chair on Cardiometabolic Risk) 7. Steffens S, Mach F (2008). Adiponectin and adaptive immunity: Linking the bridge
from obesity to atherogenesis (Editorial) Circulation Research, 102(2): 140-2

September 27, 2011

Source: http://www.cardiology-geneva.ch/documentation/sabine_steffens/publication.pdf

tamesideandglossopccg.org

TAMESIDE & GLOSSOP PCT Service Specification for Local Enhanced Service Monitoring of Disease Modifying Drugs for Rheumatological and other Medical Conditions 1. Service Users The Local Enhanced Service for the Monitoring of Disease Modifying Drugs for Rheumatological and other Medical Conditions shall be provided to Registered Patients that are taking the

Efficacy

A Review of the Efficacy and Side Effects of Introduction…………………………………………………………………….…………3 Methodology………………………………………………………………………………4 Results…………………………………………………………………………………….5 Efficacy…………………………

Copyright © 2010-2018 Pharmacy Drugs Pdf